Investor Relations

Investor Relations

NYSE American Symbol SYN
Day Low/High
52 Week Low/High

Analyst Coverage

A.G.P. / Alliance Global PartnersJames Molloy

Maxim GroupJason McCarthy, Ph.D


Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company’s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

View Profile


Our experienced management team holds an extensive clinical and commercial track record.

Investor Relations

Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209
T: (303) 282-4800